A multicenter phase II trial of docetaxel and capecitabine as salvage treatment in anthracycline- and taxane-pretreated patients with metastatic breast cancer

Karachaliou, Niki; Ziras, N.; Syrigos, Kostas; Tryfonidis, K.; Papadimitraki, E.; Kontopodis, E.; Bozionelou, V.; Kalykaki, A.; Georgoulias, Vassilis; Mavroudis, Dimitris

doi:10.1007/s00280-012-1901-3

Cited by 12 publications

(6 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Capecitabine treatment is used in patients with disease resistant to anthracycline or taxanes treatment [ 141 ]. It is used as oral prodrug to generate 5FU in tumor tissue through activation pathway of thymidine phosphorylase.…”

Section: Treatments Of Metastatic Breast Cancermentioning

confidence: 99%

Metastatic and triple-negative breast cancer: challenges and treatment options

Al-Mahmood

Sapiezynski

Garbuzenko

et al. 2018

Drug Deliv. and Transl. Res.

396

258

View full text Add to dashboard Cite

The major current conventional types of metastatic breast cancer (MBC) treatments include surgery, radiation, hormonal therapy, chemotherapy, or immunotherapy. Introducing biological drugs, targeted treatment and gene therapy can potentially reduce the mortality and improve the quality of life in patients with MBC. However, combination of several types of treatment is usually recommended. Triple negative breast cancer (TNBC) accounts for 10–20% of all cases of breast carcinoma and is characterized by the low expression of progesterone receptor (PR), estrogen receptor (ER), and human epidermal growth factor receptor 2 (HER2). Consequently, convenient treatments used for MBC that target these receptors are not effective for TNBC which therefore requires special treatment approaches. This review discusses the occurrence of MBC, the prognosis and predictive biomarkers of MBC, and focuses on the novel advanced tactics for treatment of MBC and TNBC. Nanotechnology-based combinatorial approach for the suppression of EGFR by siRNA and gifitinib is described.

show abstract

Section: Treatments Of Metastatic Breast Cancermentioning

confidence: 99%

Metastatic and triple-negative breast cancer: challenges and treatment options

Al-Mahmood

Sapiezynski

Garbuzenko

et al. 2018

Drug Deliv. and Transl. Res.

396

258

View full text Add to dashboard Cite

show abstract

“…Metastatic patients who develop resistance to anthracycline have shown sensitivity to capecitabine, gemcitabine and vinorelbine ( 77 – 79 ). The combination of docetaxel with capecitabine has improved the OS of patients with metastatic TNBC ( 78 ).…”

Section: Conventional Mode Of Treatment In Tnbcmentioning

confidence: 99%

Triple‑negative breast cancer: A run‑through of features, classification and current therapies (Review)

Manjunath

Choudhary

2021

Oncol Lett

View full text Add to dashboard Cite

“…The response rate of capecitabine plus docetaxel or vinorelbine was about 42-60%, and the median PFS was 6.1-9.3 months [16,17,18]. But data about capecitabine in TNBC patients are limited.…”

Section: Discussionmentioning

confidence: 99%

“…Until now, trials about capecitabine-based regimens in TNBC were rare, and the results were inconsistent, so we designed this prospective nonrandomized phase II trial. Preclinical data suggested synergistic activity of capecitabine with vinorelbine or docetaxel, the response rates of the combinations in breast cancer patients were about 42-55% [16,17,18]. Considering the efficacy and adverse events of docetaxel or vinorelbine and the low incidence of metastatic TNBC (mTNBC), to ensure the recruitment, either docetaxel plus capecitabine (TX) or vinorelbine plus capecitabine (NX) was allowed in our study, and was given at the discretion of the investigators.…”

Section: Introductionmentioning

confidence: 99%

Acceptable but Limited Efficacy of Capecitabine-Based Doublets in the First-Line Treatment of Metastatic Triple-Negative Breast Cancer: A Pilot Study

Liao

Fan²,

Wan³

et al. 2013

Chemotherapy

View full text Add to dashboard Cite

Background: This open-label, nonrandomized phase II clinical trial investigated the efficacy of capecitabine-based doublets in the first-line treatment of metastatic triple-negative breast cancer (mTNBC). Methods: Eligible mTNBC women with measurable diseases were recruited to receive either TX regimen (docetaxel 75 mg/m² i.v. on day 1 plus capecitabine 1,000 mg/m² b.i.d. on days 1-14 every 3 weeks) or NX regimen (vinorelbine 25 mg/m² i.v. on days 1 and 8 plus capecitabine 1,000 mg/m² b.i.d. on days 1-14 every 3 weeks) for up to 6 cycles until disease progression or unacceptable toxicity. The primary end point was objective response rate (ORR) and secondary end points included progression-free survival (PFS), overall survival (OS) and clinical benefit rate (CBR). Results: Forty-five mTNBC patients, 27 in TX and 18 in NX were recruited. The total ORR was 20.0% and CBR was 40%. After a median follow-up of 28 months, PFS was 5.2 months (95% CI, 4.1-6.3 months) and OS was 18.2 months (95% CI, 8.7-27.7 months). The response rate was numerically but not statistically lower in the TX group than in the NX group (27.8 vs. 14.8%, p = 0.449). No difference was found in either PFS (4.9 vs. 5.2 months, p = 0.483) or OS (21.5 vs. 18.3 months, p = 0.964) between the two regimens. Conclusions: Although the OS seems to be reasonable, the efficacy of capecitabine-containing TX or NX regimen was limited in terms of response and PFS in mTNBC patients, suggesting capecitabine-based doublet may be acceptable but has limited potency in this subtype.

show abstract

A multicenter phase II trial of docetaxel and capecitabine as salvage treatment in anthracycline- and taxane-pretreated patients with metastatic breast cancer

Abstract: The DC combination is a valuable regimen as salvage treatment in anthracycline- or anthracycline and taxane-pretreated patients with MBC.

Cited by 12 publications

References 41 publications

Metastatic and triple-negative breast cancer: challenges and treatment options

Metastatic and triple-negative breast cancer: challenges and treatment options

Triple‑negative breast cancer: A run‑through of features, classification and current therapies (Review)

Acceptable but Limited Efficacy of Capecitabine-Based Doublets in the First-Line Treatment of Metastatic Triple-Negative Breast Cancer: A Pilot Study

Contact Info

Product

Resources

About